US 12,012,610 B2
Engineered multi-component system for identification and characterisation of T-cell receptors and T-cell antigens
Reagan Micheal Jarvis, Stockholm (SE); Ryan Edward Hill, Stockholm (SE); and Luke Benjamin Pase, Stockholm (SE)
Assigned to Genovie AB, Södertälje (SE)
Appl. No. 16/347,684
Filed by GENOVIE AB, Södertälje (SE)
PCT Filed Nov. 7, 2017, PCT No. PCT/EP2017/078376
§ 371(c)(1), (2) Date May 6, 2019,
PCT Pub. No. WO2018/083316, PCT Pub. Date May 11, 2018.
Claims priority of application No. PA 2016 70872 (DK), filed on Nov. 7, 2016.
Prior Publication US 2019/0359934 A1, Nov. 28, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/071 (2010.01); A61K 35/15 (2015.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01)
CPC C12N 5/0602 (2013.01) [A61K 35/15 (2013.01); C07K 14/7051 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); C12N 2310/153 (2013.01); C12N 2310/18 (2013.01); C12N 2810/10 (2013.01)] 34 Claims
 
1. A multicomponent system, comprising:
as Component A, an engineered antigen presenting cell (eAPC), wherein the eAPC lacks endogenous surface expression of at least one family of target HLA class I, target HLA class II, or target non-HLA antigen-presenting complex (aAPX) and a target analyte antigenic molecule (aAM), and further comprises a single Component B,
wherein Component B is a first genomic receiver site for integration of at least one open reading frame (ORF) encoding at least one aAPX and/or aAM, wherein Component B is a synthetic construct designed for recombinase mediated cassette exchange (RMCE); and
as Component C, a first genetic donor vector for delivery of (i) a single ORF encoding at least one of the target aAPX and the target aAM; or (ii) two or more ORFs encoding at least one of the target aAPX and the target aAM, wherein Component C is matched to recombine with Component B.